August 24, 2011
Press Release No. 1
News about Lupin Limited
The media had reports that Japanese Drugmaker Takeda
is in talks to buy Lupin Limited's pharma business.
The Exchange, in order to verify the accuracy or
otherwise of the information reported in the media and to inform the market
place so that the interest of the investors is safeguarded, had written to the
company.
Lupin Limited has vide its letter inter-alia
stated,"In this regard, please note that the Company is not in discussions
with Takeda for the purposes of selling its domestic formulations business as
mentioned in the aforesaid article. As such, the news report referred above is
entirely baseless and speculative in nature and does not merit any explanation
from us."
Press Release No. 2
News about Cipla Limited
The media had reports that Japanese Drugmaker Takeda
is in talks to buy Cipla Limited's pharma business.
The Exchange, in order to verify the accuracy or
otherwise of the information reported in the media and to inform the market
place so that the interest of the investors is safeguarded, had written to the
company.
Cipla Limited has vide its letter inter-alia stated,
"The news item is baseless, untrue and is categorically denied."
Press Release No. 3
NSE completes its 2874th
Normal Settlement
The Exchange has
successfully completed its 2874th Normal
Settlement (Rolling T+2 following SEBI directive) since inception i.e.,
Settlement Number N – 2011160 on Aug 24, 2011. The settlement statistics are as
follows:
Particulars
|
Value
|
|
N-2011160
|
Total traded quantity (lakhs) |
5369.78 |
Total traded value (Rs. In Crores) |
9617.06 |
Total value of the settlement (Securities) (Rs. In Crores) |
2706.24 |
Total value of the settlement (Funds) (Rs. In Crores) |
844.13 |
Shortages for the settlement
|
0.18% |
% of Delivery ( No. of shares
deliverable / No. of shares traded ) |
28.73% |
Retail Debt
Market has completed its 2147th settlements, details of which are as
follows:
Settlement No. |
Traded Value |
Settlement Value |
|
|
|
Securities |
Funds |
D- 2011160 |
NIL |
NIL |
NIL |